Literature DB >> 22605906

Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Jordan Baye.   

Abstract

Entities:  

Year:  2012        PMID： 22605906      PMCID： PMC3351880     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  30 in total

1.  Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.

Authors:  Thomas D Bethke; Gabriele M Böhmer; Robert Hermann; Bernhard Hauns; Richard Fux; Klaus Mörike; Michael David; Dietrich Knoerzer; Wilhelm Wurst; Christoph H Gleiter
Journal:  J Clin Pharmacol       Date:  2007-01       Impact factor: 3.126

2.  Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

Authors:  Bernhard Hauns; Robert Hermann; Andreas Hünnemeyer; Rolf Herzog; Dieter Hauschke; Karl Zech; Thomas D Bethke
Journal:  J Clin Pharmacol       Date:  2006-10       Impact factor: 3.126

3.  The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.

Authors:  Robert Hermann; Werner Siegmund; Thomas Giessmann; Kristin Westphal; Anita Weinbrenner; Bernhard Hauns; Felix Reutter; Gezim Lahu; Karl Zech; Thomas D Bethke
Journal:  J Clin Pharmacol       Date:  2007-08       Impact factor: 3.126

4.  The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

Authors:  Gabriele M Böhmer; Nassr Nassr; Marcus Wenger; Andreas Hünnemeyer; Gezim Lahu; Silke Templin; Christoph H Gleiter; Robert Hermann
Journal:  J Clin Pharmacol       Date:  2009-04       Impact factor: 3.126

5.  Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.

Authors:  T D Bethke; T Giessmann; K Westphal; A Weinbrenner; B Hauns; D Hauschke; M David; G Lahu; K Zech; R Hermann; W Siegmund
Journal:  Int J Clin Pharmacol Ther       Date:  2006-11       Impact factor: 1.366

6.  Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Authors:  Gezim Lahu; Andreas Huennemeyer; Oliver von Richter; Robert Hermann; Rolf Herzog; Nigel McCracken; Karl Zech
Journal:  J Clin Pharmacol       Date:  2008-08-29       Impact factor: 3.126

7.  Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  Klaus F Rabe; Eric D Bateman; Denis O'Donnell; Stephan Witte; Dirk Bredenbröker; Thomas D Bethke
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

8.  Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.

Authors:  Nassr Nassr; Gezim Lahu; Oliver von Richter; Felix Reutter; Dietrich Knoerzer; Karl Zech; Katharina A Erb; Barbara Schug; Henning Blume; Robert Hermann
Journal:  Br J Clin Pharmacol       Date:  2006-09-29       Impact factor: 4.335

9.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Authors:  Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

10.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Authors:  Leonardo M Fabbri; Peter M A Calverley; José Luis Izquierdo-Alonso; Daniela S Bundschuh; Manja Brose; Fernando J Martinez; Klaus F Rabe
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321
View more
  13 in total

Review 1.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

2.  Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.

Authors:  Hussam A Murad; Hamed S Habib; Misbahuddin M Rafeeq; Mansour I Sulaiman; Amer S Abdulrahman; Mohamad Nidal Khabaz
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-05

3.  Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.

Authors:  Alex Z Fu; Shawn X Sun; Xingyue Huang; Alpesh N Amin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-05-12

4.  The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease.

Authors:  Kyung-Hwa Jung; Kyoung-Keun Haam; Soojin Park; Youngeun Kim; Seung Ryel Lee; Geunhyeog Lee; Miran Kim; Moochang Hong; Minkyu Shin; Sungki Jung; Hyunsu Bae
Journal:  BMC Complement Altern Med       Date:  2013-09-05       Impact factor: 3.659

Review 5.  Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.

Authors:  Eric P Knott; Mazen Assi; Sudheendra N R Rao; Mousumi Ghosh; Damien D Pearse
Journal:  Int J Mol Sci       Date:  2017-03-24       Impact factor: 5.923

Review 6.  Phosphodiesterase 4B: Master Regulator of Brain Signaling.

Authors:  Amy J Tibbo; George S Baillie
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

7.  Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial.

Authors:  Arschang Valipour; Sebastian Fernandez-Bussy; Alvin J Ing; Daniel P Steinfort; Gregory I Snell; Jonathan P Williamson; Tajalli Saghaie; Louis B Irving; Eli J Dabscheck; William S Krimsky; Jonathan Waldstreicher
Journal:  Am J Respir Crit Care Med       Date:  2020-09-01       Impact factor: 21.405

Review 8.  Positioning new pharmacotherapies for COPD.

Authors:  Igor Z Barjaktarevic; Anthony F Arredondo; Christopher B Cooper
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-24

9.  Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.

Authors:  Floriane Montanari; Anna Cseke; Katrin Wlcek; Gerhard F Ecker
Journal:  SLAS Discov       Date:  2016-07-11       Impact factor: 3.341

Review 10.  New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.

Authors:  Manar Mohammed El Tabaa; Maram Mohammed El Tabaa
Journal:  Eur J Pharmacol       Date:  2020-10-01       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.